Phathom Pharmaceuticals Revenue Jumps 88% on VOQUEZNA Growth

Key Facts

1Phathom Pharmaceuticals reported Q2 2026 revenue of $74.3M, representing an 88% increase.

2Management forecasts full-year 2026 revenue between $310M and $325M with an 80% gross margin.

3The company holds $182.5M in cash to support commercial runway despite risks from revenue-interest financing.

Amid the commercial scaling of emerging biotech firms, Phathom Pharmaceuticals has reported a significant surge in its financial results. The company achieved revenue of $74.3 million in the second quarter of 2026, representing an 88% increase. This robust growth is primarily attributed to the increased adoption of its drug VOQUEZNA among specialists, supported by a commercial strategy targeting gastroenterologists and improved operating leverage as SG&A expenses declined.

The company's financial data reflects optimism regarding future performance, with management forecasting full-year 2026 revenue between $310 million and $325 million, targeting a high gross margin of 80%. According to reports, Phathom holds $182.5 million in cash to support its commercial runway, although certain risks remain regarding revenue-interest financing that could impact the long-term financial structure.

Operationally, Phathom has completed a nationwide sales-territory redistribution to bolster its specialist-focused efforts. Based on available data as of September 9, 2026, specific price levels for PHAT are unavailable in the current database; however, the outlook remains positive based on strong commercial execution. Investors are monitoring the sustainability of sales growth in the biotech sector as a primary catalyst moving forward.